CRI market research report

Dysmenorrhea Treatment Market—Forecast till 2027

$4950 – $7250

The global dysmenorrhea treatment market is anticipated to witness a healthy market expansion at a CAGR of 7.9% to surpass USD 6,312.88 million by 2027.

SKU: MRFR220262 Category: Tag:

Description

Dysmenorrhea Treatment Market- Forecast till 2027

Market Overview
The global dysmenorrhea treatment market is anticipated to witness a healthy market expansion at a CAGR of 7.9% to surpass USD 6,312.88 million by 2027.

It is a commonly found disease in women during their menstrual cycle. The changing life and diet impacted the menstrual cycle among ladies. High work pressure, tension deferred the feminine cycle and furthermore caused variable feminine issues. Besides, the ladies impacted by Covid experienced excruciating periods alongside changes in chemical levels and anomalies in the cycle.

Such factors drive the dysmenorrhea treatment market and are projected to produce a nice market development in the anticipated time span.

The global market growth is driven by the growing occurrences of dysmenorrhea among teenage girls and increasing cases of menstrual cramps because of genetic disorders. However, the negative impact on products due to side effects caused by the products is expected to restrain the market growth during the review period.

The female populace in creating and immature nations faces feminine issues because of restricted mindfulness about treatment, a cultural tension, and different variables. Worldwide wellbeing associations, for example, WHO screen the feminine wellbeing status of ladies and young ladies internationally.

Market Segmentation
The global dysmenorrhea treatment market has been divided based on type, type of treatment, and end-user.
Based on Product Type the global market has been bifurcated into Primary Dysmenorrhea and Secondary Dysmenorrhea.
By Type of Treatment, the market is classified as Pain Relievers, Hormonal Therapy, Surgery, and Others. The End-User segment is further categorized into Hospitals & Clinics, Research Centres, and Others.

Regional Analysis
The region-specific analysis of the global dysmenorrhea treatment market is spread across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas represented the biggest offer in the dysmenorrhea treatment market and is relied upon to keep ruling the market before very long. A lot of this expected interest for dysmenorrhea treatment can be credited to the expanding number of patients experiencing feminine problems.
The dysmenorrhea treatment market in Europe represented the second-biggest income-producing district internationally.

The clinical preliminaries zeroed in on diminishing agony related to dysmenorrhea are relied upon to build the quantity of accessible viable treatment choices during the estimated time frame.

Asia-Pacific is one of the quickest developing dysmenorrhea treatment provincial markets during the survey time frame. The elements essentially answerable for the development of the dysmenorrhea treatment market in the region are the expanding populace and the ascent in the degree of mindfulness about the condition made by the government.

The Middle East and Africa dysmenorrhea treatment market represented the least market share and is relied upon to observe huge development before very long during the figure time frame.

Major Players
The prominent companies operating in the global dysmenorrhea market are Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Focus Consumer Healthcare, LLC (US), Novartis AG (Switzerland), Pfizer, Inc. (US), Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France), and Viatris Inc. (US).

COVID 19 Impacts
We are continuously tracking the impact of COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.

Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 2.2 RESEARCH OBJECTIVE 2.3 MARKET STRUCTURE 2.4 ASSUMPTIONS & LIMITATIONS 3 RESEARCH METHODOLOGY 3.1 OVERVIEW 3.2 DATA MINING 3.3 SECONDARY RESEARCH 3.4 PRIMARY RESEARCH 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 INCREASING PREVALENCE OF DYSMENORRHEA AMONG ADOLESCENT GIRLS 4.2.2 INCREASING CASES OF MENSTRUAL CRAMPS DUE TO GENETIC DISORDERS 4.3 RESTRAINTS 4.3.1 CONCERNS PERTAINING TO SIDE EFFECTS 4.3.2 HIGH AVAILABILITY OF ALTERNATIVE PRODUCTS 4.4 OPPORTUNITIES 4.4.1 THE EMERGENCE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR DYSMENORRHEA TREATMENT 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 R&D AND DESIGNING 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION, MARKETING, & SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER'S FIVE FORCES MODEL 5.2.1 THREAT OF NEW ENTRANTS 5.2.2 BARGAINING POWER OF SUPPLIERS 5.2.3 THREAT OF SUBSTITUTES 5.2.4 BARGAINING POWER OF BUYERS 5.2.5 INTENSITY OF RIVALRY 5.3 COVID-19 IMPACT ANALYSIS 5.3.1 IMPACT ON WOMEN'S HEALTH 5.3.2 IMPACT ON TREATMENT 6 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE 6.1 OVERVIEW 6.2 PRIMARY DYSMENORRHEA 6.3 SECONDARY DYSMENORRHEA 7 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT 7.1 OVERVIEW 7.2 PAIN RELIEVERS 7.3 HORMONAL THERAPY 7.4 SURGERY 7.5 OTHERS 8 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER 8.1 OVERVIEW 8.2 HOSPITALS & CLINICS 8.3 RESEARCH CENTRES 8.4 OTHERS 9 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY REGION 9.1 INTRODUCTION 9.2 AMERICAS 9.2.1 NORTH AMERICA 9.2.1.1 US 9.2.1.2 CANADA 9.2.2 LATIN AMERICA 9.3 EUROPE 9.3.1 WESTERN EUROPE 9.3.1.1 GERMANY 9.3.1.2 FRANCE 9.3.1.3 UK 9.3.1.4 ITALY 9.3.1.5 SPAIN 9.3.1.6 REST OF WESTERN EUROPE 9.3.2 EASTERN EUROPE 9.4 ASIA PACIFIC 9.4.1 CHINA 9.4.2 INDIA 9.4.3 JAPAN 9.4.4 AUSTRALIA 9.4.5 SOUTH KOREA 9.4.6 REST OF ASIA PACIFIC 9.5 MIDDLE EAST & AFRICA 9.5.1 MIDDLE EAST 9.5.2 AFRICA 10 COMPETITIVE LANDSCAPE 10.1 OVERVIEW 10.2 COMPETITIVE BENCHMARKING 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET 10.5 KEY DEVELOPMENT ANALYSIS 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 10.6.1 MERGER/ACQUISITION 10.7 FINANCIAL MATRIX 10.7.1 SALES (USD MILLION), 2020 10.7.2 R&D EXPENDITURE (USD MILLION), 2020 11 COMPANY PROFILES 11.1 NOVARTIS AG 11.1.1 COMPANY OVERVIEW 11.1.2 FINANCIAL OVERVIEW 11.1.3 PRODUCTS/SERVICES OFFERED 11.1.4 KEY DEVELOPMENTS 11.1.5 SWOT ANALYSIS 11.1.6 KEY STRATEGIES 11.2 PFIZER, INC. 11.2.1 COMPANY OVERVIEW 11.2.2 FINANCIAL OVERVIEW 11.2.3 PRODUCTS/SERVICES OFFERED 11.2.4 KEY DEVELOPMENTS 11.2.5 SWOT ANALYSIS 11.2.6 KEY STRATEGIES 11.3 RECKITT BENCKISER GROUP PLC. 11.3.1 COMPANY OVERVIEW 11.3.2 FINANCIAL OVERVIEW 11.3.3 PRODUCTS/SERVICES OFFERED 11.3.4 KEY DEVELOPMENTS 11.3.5 SWOT ANALYSIS 11.3.6 KEY STRATEGIES 11.4 SANOFI S.A. 11.4.1 COMPANY OVERVIEW 11.4.2 FINANCIAL OVERVIEW 11.4.3 PRODUCTS/SERVICES OFFERED 11.4.4 KEY DEVELOPMENTS 11.4.5 SWOT ANALYSIS 11.4.6 KEY STRATEGIES 11.5 VIATRIS INC. 11.5.1 COMPANY OVERVIEW 11.5.2 FINANCIAL OVERVIEW 11.5.3 PRODUCTS/SERVICES OFFERED 11.5.4 KEY DEVELOPMENTS 11.5.5 SWOT ANALYSIS 11.5.6 KEY STRATEGIES 11.6 JOHNSON & JOHNSON SERVICES INC. 11.6.1 COMPANY OVERVIEW 11.6.2 FINANCIAL OVERVIEW 11.6.3 PRODUCTS/SERVICES OFFERED 11.6.4 KEY DEVELOPMENTS 11.6.5 SWOT ANALYSIS 11.6.6 KEY STRATEGIES 11.7 GLAXOSMITHKLINE PLC 11.7.1 COMPANY OVERVIEW 11.7.2 FINANCIAL OVERVIEW 11.7.3 PRODUCTS/SERVICES OFFERED 11.7.4 KEY DEVELOPMENTS 11.7.5 SWOT ANALYSIS 11.7.6 KEY STRATEGIES 11.8 F. HOFFMANN-LA ROCHE LTD 11.8.1 COMPANY OVERVIEW 11.8.2 FINANCIAL OVERVIEW 11.8.3 PRODUCTS/SERVICES OFFERED 11.8.4 KEY DEVELOPMENTS 11.8.5 SWOT ANALYSIS 11.8.6 KEY STRATEGIES 11.9 BAYER AG 11.9.1 COMPANY OVERVIEW 11.9.2 FINANCIAL OVERVIEW 11.9.3 PRODUCTS/SERVICES OFFERED 11.9.4 KEY DEVELOPMENTS 11.9.5 SWOT ANALYSIS 11.9.6 KEY STRATEGIES 11.10 FOCUS CONSUMER HEALTHCARE, LLC 11.10.1 COMPANY OVERVIEW 11.10.2 FINANCIAL OVERVIEW 11.10.3 PRODUCTS/SERVICES OFFERED 11.10.4 KEY DEVELOPMENTS 11.10.5 SWOT ANALYSIS 11.10.6 KEY STRATEGIES 12 APPENDIX 12.1 REFERENCES 12.2 RELATED REPORTS

Companies Mentioned

Johnson & Johnson (US) GlaxoSmithKline PLC (UK) Hoffmann-La Roche Ltd (Switzerland) Bayer AG (Germany) Focus Consumer Healthcare LLC (US) Novartis AG (Switzerland) Pfizer Inc. (US) Reckitt Benckiser Group plc. (UK) Sanofi S.A. (France) and Viatris Inc. (US)

Reviews

There are no reviews yet.

Be the first to review “Dysmenorrhea Treatment Market—Forecast till 2027”

Related products